Loading...
XTAE
BOLT
Market cap6mUSD
Jul 09, Last price  
370.70ILS
1D
0.95%
1Q
29.48%
Jan 2017
-70.91%
IPO
-99.22%
Name

Biolight Life Sciences Ltd

Chart & Performance

D1W1MN
XTAE:BOLT chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
5.47%
Rev. gr., 5y
-5.91%
Revenues
0k
-100.00%
52,00082,000941,0001,391,0002,111,0001,209,0003,687,000297,00031,0003,00063,000118,000219,0000
Net income
-12m
L+64.20%
-13,356,000-18,837,000-23,102,000-19,259,000-21,824,000-17,260,00065,385,000-12,591,000-13,382,000382,000-7,847,000-26,020,000-7,142,000-11,727,000
CFO
-11m
L-1.27%
-19,460,000-26,225,000-26,987,000-24,037,000-26,942,000-25,318,000-22,390,000-15,357,000-11,395,000-10,026,000-9,540,000-9,577,000-10,994,000-10,854,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

BioLight Life Sciences Ltd. is an ophthalmic firm dedicated to discovering, developing, and bringing to market innovative products and pipeline candidates designed to tackle various eye-related ailments. Its portfolio and development pipeline include DiagnosTear's TeaRx, a diagnostic platform analyzing tear fluid components to identify frontal eye diseases, and Peripherex, offering solutions for both at-home and clinical diagnosis and monitoring of peripheral vision loss, crucial for conditions like glaucoma. For glaucoma, BioLight features ViSci (an Eye D technology utilizing a subconjunctival implant), Belkin Vision's rapid, automated laser system for effective intraocular pressure reduction, and Sanoculis, which is advancing a novel surgical approach. The company also encompasses OphRx, focused on developing pharmaceutical treatments for ocular disorders; AEYE, which designs artificial intelligence-powered solutions for diverse retinal conditions; and Tarsier, working on TRS 01, a platform-based treatment for uveitis in patients with elevated intraocular pressure. Founded in 2005, the Tel Aviv, Israel-based company operated as Bio Light Israeli Life Sciences Investments Ltd. until its rebranding to BioLight Life Sciences Ltd. in February 2016.
URL
https://www.bio-light.co.il
IPO date
Dec 27, 2005
Employees
5
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT